AstraZeneca shared a post LinkedIn:
“Today we announced plans to establish a new global strategic R/D centre in Beijing to advance our global efforts to bring innovative medicines to patients worldwide.
This investment reflects the rapid advancement of Beijing’s world-class life sciences ecosystem, the extensive opportunities for collaboration, access to talent, and our continued commitment to China.
Beijing will become our second strategic R/D centre in China, alongside Shanghai, and our sixth worldwide, with two centres in the US and two in Europe.”
